Curevo Vaccine

Executive Summary

Curevo Vaccine is a clinical-stage biotechnology company focused on developing next-generation non-mRNA vaccines using adjuvanted subunit technology. The company's lead candidate, currently in Phase 3 trials, targets an unmet medical need in infectious disease, leveraging a proprietary adjuvant to enhance immune response while maintaining a favorable tolerability profile. With a streamlined strategy of concentrating on one vaccine at a time, Curevo aims to bring a more effective and better-tolerated alternative to existing mRNA-based or live-attenuated vaccines, addressing both efficacy and safety concerns in vulnerable populations. The company is headquartered in Seattle and was founded in 2020, with a clear mission to deliver non-mRNA solutions for high-burden diseases. As Curevo advances through Phase 3, key catalysts include the release of pivotal efficacy and safety data from its ongoing trial, which could support a Biologics License Application (BLA) submission. If successful, the vaccine could capture significant market share by offering a differentiated profile. The company's focus on adjuvanted subunit technology positions it well in a landscape where there is growing demand for non-mRNA alternatives, particularly for boosting or primary vaccination in immunocompromised individuals. With a strong scientific rationale and a late-stage asset, Curevo represents a compelling opportunity in the vaccine space.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-line Data Readout70% success
• Q4 2026Regulatory Submission (BLA) Initiation60% success
• TBDPartnership or Licensing Agreement for ex-US Rights50% success